News
Shares of Verve Therapeutics skyrocketed 75% Tuesday morning after Eli Lilly announced that it would acquire the gene-editing startup for about $1.3 billion.
Eli Lilly's (LLY) $1.3B Verve Therapeutics (VERV) acquisition offers investors a 70%+ premium. See why I think this deal is beneficial to both companies.
Eli Lilly LLY 0.62% agreed to acquire Verve Therapeutics VERV -0.27% for about $1 billion upfront, adding a potential treatment for cardiovascular disease to its portfolio. Under the agreement ...
Eli Lilly (LLY) will acquire Verve Therapeutics (VERV) for up to $13.5/share, aiming to revolutionize cholesterol treatment. Read more on my thoughts on this deal.
With acquisition of Verve Therapeutics, Eli Lilly aims to advance next-generation cardiovascular care through one-time gene editing treatments.
The acquisition aligns with Eli Lilly’s broader diversification strategy beyond its core diabetes and obesity treatment portfolio.
We came across a bullish thesis on Verve Therapeutics, Inc. on Stock Region Research’s Substack by Stock Region. In this ...
Eli Lilly (NYSE:LLY) is taking a big swing into gene editing with a deal to buy Verve (NASDAQ:VERV) Therapeutics for up to $1.3 billion, paying $10.50 per share in cash plus a contingent right ...
Eli Lilly will acquire gene-editing startup Verve Therapeutics for up to $1.3 billion, the companies said on Tuesday, accelerating a push into experimental cardiovascular therapies.
Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (Nasdaq: VERV), a Boston-based clinical-stage company developing genetic medicines for cardiovascular disease, today announced a ...
Eli Lilly has announced its intention to acquire Verve Therapeutics, a biotechnology company specializing in gene-editing therapies for cardiovascular diseases, in a deal valued at up to $1.3 billion.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results